Get the latest tech news
'Extremely impressive': melanoma jab trial results excite doctors
Vaccine approach will help improve survival rates for ‘the next decades and more’, says Cancer Research UK’s chief clinician
The world’s first personalised mRNA cancer vaccine for melanoma halves the risk of patients dying or the disease returning, according to trial results that doctors described as “extremely impressive”. Patients who received the vaccine after having a stage 3 or 4 melanoma removed had a 49% lower risk of dying or the disease recurring after three years, data presented at the world’s largest cancer conference showed. The lead author, Dr Christian Singer, said: “This is the first significant and profound long-term survival benefit of an anti-cancer vaccine in breast cancer patients reported to date.”
Or read this on Hacker News
